Good, but deep stuff. On a tangentially related topic, I've read some of the animal models of Glioblstoma concerning VB-111. They show prolonged survival, reduction of tumor mass, but one, very intriguing model showed a percentage of 15-20 % of animals had elimination of the brain tumor.
So, hopefully, based on the phase II, animal models, and some unblinded patient accounts in the phase III, what you have is a certain percentage of non-responders or in line of the temporizing effects of Avastin, a plurality of patients showing better tumor control than avastin... especially in best RANO tumor reductions plus the all-important metric of survival after progression, i.e. a slower decay in terms of the rate of tumor increase, and a minority, 10 %, in the phase II of complete responders. The variability may have to do with the robustness of the immune response in individual patents.
News 
Market Data 
Discover 
